Biohaven Ltd.

BHVN Healthcare Biotechnology

In the quarter to June 2026, EPS grew 53.1%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

10.78 0.65 −5.69%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−49.0×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
4.73 7.41 3.18 2.86
Net Debt/EBITDA
0.07 0.83 0.57 (0.05)
Debt/Equity
21.23 1.87 4.59 (15.63)
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.57) (1.02) (1.21) (1.38)
Book value per Share
0.08 0.88 0.48 (0.16)
Free Cash Flow
(85.55) (149.92) (130.67) (145.73)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates